Form 4: ACADIA CFO Sells Shares After RSU Vesting

Acadia Pharmaceuticals' EVP and CFO, Mark C. Schneyer, sold 3,506 shares of common stock to cover tax obligations following the vesting of 6,815 restricted stock units.

Summary

• Mark C. Schneyer, Executive Vice President and Chief Financial Officer of ACADIA PHARMACEUTICALS INC, reported transactions involving the company's common stock.
• On May 1, 2026, 6,815 restricted stock units (RSUs) vested, converting into 6,815 shares of common stock.
• Following the RSU vesting, the beneficial ownership of common stock increased to 69,651 shares.
• On May 4, 2026, Mr. Schneyer disposed of 3,506 shares of common stock at a weighted average price of $21.79 per share.
• This sale was mandatory and intended to cover withholding taxes and tax-related items associated with the RSU vesting.
• The sale was executed under a Rule 10b5-1(c) plan, indicating it was pre-scheduled.
• After the sale, Mr. Schneyer's direct beneficial ownership of common stock stands at 66,145 shares.
• The restricted stock units vest in four equal annual installments, with the first installment beginning May 1, 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine, pre-planned sale to cover tax obligations arising from RSU vesting, which is a common compensation practice and does not reflect a change in the executive's outlook on the company's fundamentals.

Positives

• The vesting of 6,815 restricted stock units represents a realization of compensation for the EVP and CFO, indicating continued alignment of executive interests with shareholder value.
• The sale was conducted under a Rule 10b5-1 plan, which demonstrates a pre-planned and transparent approach to insider transactions, mitigating concerns about opportunistic selling.

Negatives

• The sale of 3,506 shares by a key executive, even if tax-related, reduces the executive's direct equity stake in the company.

Industry Context

StockSavvy.ai notes that tax-related sales by executives following RSU vesting are a common and routine occurrence across industries. The use of a Rule 10b5-1 plan for such transactions is standard practice, providing a legal framework for insiders to sell company stock without being accused of trading on material non-public information.

Stakeholder Impact

• Shareholders: The impact on shareholders is minimal, as this is a routine, tax-related insider transaction and does not signal a change in company fundamentals or executive confidence beyond the pre-planned nature of the sale.

Key Dates

Recommendation

A 'hold' recommendation is appropriate as this Form 4 filing details a routine, pre-planned insider transaction (sale to cover taxes after RSU vesting) by the EVP and CFO. Such transactions, especially when executed under a Rule 10b5-1 plan, are common and generally do not indicate a change in the company's operational performance, strategic direction, or the executive's long-term confidence. Investors should not interpret this as a signal to buy or sell based solely on this filing, but rather continue to evaluate the company based on its financial results, strategic initiatives, and market conditions.

Keywords

ACADIA PHARMACEUTICALS, ACAD, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Sale, Rule 10b5-1, CFO